Safety and Efficacy of Low-Dosage Apatinib Monotherapy in Advanced Lung Squamous-Cell Carcinoma: A Prospective Cohort Study.

BACKGROUND: Lung squamous-cell carcinoma (SqCC) is the second most common histology in non-small-cell lung carcinomas (NSCLCs). The treatment options for advanced lung SqCC are still an unmet medical need. Apatinib, a small-molecule inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2), is beneficial in the therapy of advanced NSCLC patients. This study aimed to preliminarily assess the efficacy and safety of low-dosage apatinib in patients with advanced lung SqCC.
METHODS: In this single-arm, open-label, investigator-initiated phase II prospective study (ChiCTR1800019808), we enrolled patients aged 54-80 years with platinum-refractory or chemotherapy rejected advanced lung squamous-cell carcinoma. Key exclusion criteria included major blood vessel involvement and gross hemoptysis with an amount of more than 20 mL. Apatinib at an initial dose of 250 mg was administered to patients once daily until disease progression, unacceptable toxicity, withdrawal, or death. The primary endpoint was progression-free survival (PFS) in all patients. We assessed the adverse events according to the treatment received.
RESULTS: Thirty-eight patients were enrolled between June 11, 2015 and August 29, 2018. Two patients failed to evaluate treatment efficacy for personal reasons, and thus 36 patients were eligible for evaluation of tumor response to apatinib. Median PFS was 4.9 months (95% CI: 3.0-6.8 months). Six patients achieved partial response (PR); the objective response rate (ORR) was 16.7% (6/36), and the total disease control rate (DCR) was 77.8% (28/36). Followed up to March 2020, 35 of the 38 patients were dead, and the 1-year survival rate was 21.1% (8/38). The median overall survival (OS) was 6.9 months (95% CI: 5.2-8.5 months). The most common adverse events included fatigue (50.0%), hypertension (42.1%), proteinuria (23.7%), loss of appetite (23.1%) and hand-foot reaction (21.1%). No grade 4 adverse effect or drug-related mortality occurred.
CONCLUSIONS: Low-dose apatinib monotherapy might be an option for patients with advanced lung squamous-cell carcinoma.

Introduction

Lung cancer ranks first globally in morbidity and mortality rates among cancers. Lung squamous-cell carcinoma (SqCC), which is included in non-small cell carcinoma (NSCLC), accounts for 25–30% of lung cancer cases.1 Unlike the success obtained in the therapy of adenocarcinoma, the treatment options in advanced lung SqCC are still limited due to the lack of driver mutations and a worse prognosis.2 In patients with advanced lung SqCC, platinum-based doublet chemotherapy is the first-line standard treatment option. Unfortunately, although the chemotherapy regimen has been updated in the past 30 years, the median survival time is only 1 year for patients with stage IIIB or IV lung SqCC.3

Folkman was the first to propose the theory of tumor angiogenesis and the therapeutic conception and mechanism for anti-angiogenesis.4 Vascular endothelial growth factor (VEGF) and its receptors, especially VEGF receptor 2 (VEGFR2), are predominantly responsible for angiogenic signaling,5,6 which is an essential step in tumor growth, invasion, and metastasis.7 Antibodies against VEGF or VEGFR, bevacizumab and ramucirumab were suggested for addition to chemotherapy for advanced non–small-cell lung cancer (NSCLC) without driver mutation.8,9 Of note, bevacizumab is not approved for the treatment of lung SqCC because of the risk of hemorrhage.10,11 To date, scarce evidence exists for the application of monotherapy with antiangiogenesis drugs as second- or further-line therapy for advanced lung SqCC.

As an oral small-molecule tyrosine kinase inhibitor (TKI) available in mainland China, apatinib, which selectively binds to and inhibits VEGFR-2, has a significant effect on advanced gastric and breast cancers.12–14 Recent studies showed the efficiency of apatinib in advanced NSCLC patients.15,16 In the present pilot investigation, we aimed to explore the efficacy and safety of low-dose apatinib monotherapy in Chinese patients with advanced lung SqCC.

Materials and Methods

Study Design and Participants

We conducted a single-arm, open-label, investigator-initiated phase II prospective study at the Affiliated Changzhou No.2 People’s Hospital of Nanjing Medical University (Changzhou, China) and Lianyungang No.2 People’s Hospital (Lianyungang, China). Patients aged 54–80 years, who had platinum-refractory (defined as progression during the initial platinum-based treatment) advanced lung squamous-cell carcinoma (III–IV stage), were eligible to take part in the study. Patients who refused chemotherapy were also eligible.

Key exclusion criteria were major blood vessel involvement and gross hemoptysis with an amount of more than 20 mL. Patients of any one or more of the following conditions were also excluded: severe liver failure, severe kidney failure, and class III or IV cardiac insufficiency.

The study was approved by the Ethics Committee of the Affiliated Changzhou No.2 People’s Hospital of Nanjing Medical University, and the patients selected for the study signed consent forms.

Procedures

Patients were administered apatinib at an initial dose of 250 mg once daily and would not stop until disease progression, unacceptable toxicity, withdrawal, or death.

Dose modifications, including dose interruptions and dose reductions, were allowed for the management of adverse events. Repeated dose interruptions were permitted as required, for a maximum of 14 days on each occasion.

Two dose reductions were permitted for apatinib (250 mg and 125 mg taken on alternate days, and 125 mg once daily) in the event of toxicity. For grade 4 non-hematological toxicities, apatinib was delayed until recovery to grade 1 or better and then resumed with a reduction of one dose. At the first occurrence of grade 3 non-hematological and grade 3 or 4 hematological toxicities, apatinib was delayed until recovery to grade 1 or below non-hematological and grade 2 or below hematological toxicities, and then treatment was resumed at the same dose. On the second occurrence of grade 3 non-hematological and grade 3 or 4 hematological toxicities, patients underwent one dose reduction (to either 250 mg and 125 mg taken on alternate days or 125 mg once daily, depending on the dose level patients were on when the toxicities occurred). Dose reductions were also recommended for intolerable grade 2 events if investigators considered dose reduction necessary.

Measurable disease was assessed and documented before treatment. Tumor response according to RECIST 1.1 was assessed by investigators using CT scans after 28 days of apatinib monotherapy, and subsequently every 2 months until disease progression was confirmed. Adverse events were evaluated according to the National Cancer Institute Common Toxicity Criteria version 4.0 (CTC 4.0) and were assessed throughout the treatment cycles.

Outcomes

In all patients, the primary endpoint was progression-free survival (PFS). Secondary endpoints were objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety. PFS encompassed the time from the first day of apatinib to documented progression or death. Objective tumor responses included complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). The objective remission rate (ORR) was calculated based on CR + PR. The disease control rate (DCR) was calculated based on CR + PR + SD. OS was defined as the time from the first day of apatinib treatment to death or last follow-up. The follow-up continued until March 2020.

Statistical Analysis

We calculated the proportions of patients achieving responses and assessed 95% CIs using the Clopper–Pearson method, and the median duration of response and overall survival, and associated 95% CIs with the Kaplan–Meier method. All statistical analyses were performed using SPSS version 19.0.

Results

A total of 38 patients were enrolled in the study between June 11, 2015 and August 29, 2018 (Table 1): 97.4% male, 76.3% current/former smokers and 50.0% with ECOG 2–3 performance status. Most patients had received 1 (50.0%) or ≥2 (39.5%) prior lines of therapy. Two patients failed to evaluate efficacy for refusing CT examination, so that 36 patients were eligible for evaluation of tumor response to apatinib (Table 2). After apatinib monotherapy, partial response (PR) was achieved in six patients, stable disease (SD) in 22 patients, and progression disease (PD) in eight patients. The objective remission rate (ORR) was 16.7% (6/36) and the total disease control rate (DCR) was up to 77.8% (28/36). The median PFS of apatinib was 4.9 months (95% CI: 3.3–6.5 months) (Figures 1 and 2). The longest PFS was 360 days in a patient (250 mg/d dosage). Followed up to March 2020, 35 of 38 patients were dead, and the one-year survival rate was 21.1% (8/38). The median OS of apatinib was 6.9 months (95% CI: 5.2–8.5 months) (Figure 3).

Table 1

Baseline Patient Characteristics

	N	Percentage
Age	Mean ± SD	(67.5 ± 6.9)
Sex
Male	37	97.4%
Female	1	2.6%
Smoke history
Yes	29	76.3%
No	9	23.7%
ECOG PS
0	3	7.9%
1	16	42.1%
2	16	42.1%
3	3	7.9%
Stage
IIIA	1	2.6%
IIIB	7	18.4%
IIIC	7	18.4%
IV	23	60.5%
Number of prior regimens
0	4	10.5%
1	19	50.0%
≥2	15	39.5%

Table 2

Treatment Responses

Evaluation	N	%
CR	0	0
PR	6	16.7%
SD	22	61.1%
PD	8	22.2%

Figure 1

Waterfall plot for the progression-free survival (PFS) of the 36 patients enrolled in the study. *The columns above the horizontal axis represent the patients who achieved PD (blue), whereas the below represent the patients who achieved PR (red) and SD (yellow).

Figure 2

Kaplan–Meier graph for the progression-free survival (PFS) in patients with SqCC (n = 36).

Figure 3

Kaplan–Meier graph for the overall survival (OS) of patients in the study (n = 38).

All patients were assessed for toxicity. The incidence of adverse events (any grade) regardless of causality was 81.6% (31/38). No patients discontinued the study. The adverse effects of apatinib treatment included hypertension (16/38, 42.1%), proteinuria (9/38, 23.7%), hand-foot reaction (8/38, 21.1%), hemoptysis (7/38, 18.4%), fatigue (19/38, 50.0%), neutropenia (2/38, 5.3%), oral mucositis (4/38, 10.5%), heart dysfunction (1/38, 2.6%), abnormal liver function (1/38, 2.6%), thrombocytopenia (1/38, 2.6%) and loss of appetite (9/38, 23.7%; Table 3). Most adverse effects were from Grade 1 to Grade 2, which were tolerable and manageable. No grade 4 adverse effect or drug-related mortality occurred.

Table 3

Possible Treatment-Related Adverse Events

	I–II	III	IV	Total
Non-hematological
Hypertension	10 (26.3%)	6 (15.8%)	0	16 (42.1%)
Proteinuria	7 (18.4%)	2 (5.3%)	0	9 (23.7%)
Hand-foot reaction	8 (21.1%)	0	0	8 (21.1%)
Oral mucositis	4 (10.5%)	0	0	4 (10.5%)
Fatigue	15 (39.5%)	4 (10.5%)	0	19 (50.0%)
Loss of appetite	7 (18.4%)	2 (5.3%)	0	9 (23.7%)
Hemoptysis	7 (18.4%)	0	0	7 (18.4%)
Heart dysfunction	0	1 (2.6%)	0	1 (2.6%)
Abnormal liver function	1 (2.6%)	0	0	1 (2.6%)
Hematological
Neutropenia	2 (5.3%)	0	0	2 (5.3%)
thrombocytopenia	1 (2.6%)	0	0	1 (2.6%)

Dose reductions occurred in 5 (13.2%) of 38 patients, of whom 3 (60%) patients required only one dose reduction, and 2 (40%) patients had two dose reductions. Three (60%) of the five patients had the first dose reduction for apatinib at the completion of the first cycle, and the occurrence of the first dose reduction for apatinib was recorded in two (40%) patients during the second cycle.

Discussion

To our knowledge, up to date, there remains no randomized controlled trial focused on apatinib monotherapy in patients with advanced non-small-cell lung carcinoma. Our study reported, for the first time, the efficacy and safety of apatinib at a low-dosage of 250 or 125 mg daily in patients with platinum-refractory or chemotherapy rejected advanced lung squamous-cell carcinoma. We found that the ORR and DCR were 16.7% and 77.8%, and the median PFS and OS were 4.9 and 6.9 months, respectively. Furthermore, most adverse effects were tolerable and manageable.

As an oral anti-angiogenesis drug, apatinib selectively inhibited VEGFR-2 activation. Apatinib was beneficial to increase survival rate as compared with placebo in chemotherapy-refractory advanced gastric cancer patients in a Phase III trial (6.5 vs 4.7 months, P = 0.0149).13 Apatinib was also reported to be effective for the treatment of metastatic breast carcinoma patients who failed standard treatment (PFS 3.3 months, OS 10.7 months).14 In another study of salvage treatment with apatinib for advanced non-small-cell lung cancer, DCR and ORR were 61.9% and 9.5%, respectively.15 The values of DCR and ORR in the present investigation were 77.8% and 16.7%, correspondingly, which indicates superior efficacy over docetaxel as second-line chemotherapy in NSCLC.17 Of note, half of the patients in the present examination had PS ≥ 2, which might have an influence on the efficacy of apatinib.

The addition of bevacizumab, a representative for anti-angiogenesis drugs, to chemotherapy was beneficial to OS in advanced nonsquamous NSCLC.8 However, it has not been approved for the treatment of squamous-cell carcinoma due to severe hemoptysis.10,11 Lung SqCC has been a restricted area for anti-angiogenic drugs for a long time. Until 2014, the subgroup analysis in the REVEL study had shown that patients with SqCC seemed to have derived similar benefit from treatment with ramucirumab plus docetaxel without an increase in toxicity, particularly respiratory tract hemorrhage, when compared with the placebo group and non-squamous disease group.9 The reason that the authors concluded might be that bevacizumab was a monoclonal antibody against VEGF and ramucirumab especially against VEGFR2, which localized to tumor blood vessels.

The combination of ramucirumab and docetaxel had more pronounced beneficial effects than simple chemotherapy in the REVEL study (4.5 vs 3.0 months, P < 0.01).9 Few investigations have been focused on the efficiency of anti-angiogenic drugs as monotherapy in advanced lung SqCC. Two clinical cases were reported of NSCLC patients treated with apatinib, with PFS of 4.6 and 6 months.18 Another study found that the median PFS for advanced NSCLC patients by using oral apatinib alone as post-second-line therapy was 4.4 months. In our investigation, the use of apatinib as monotherapy in advanced lung SqCC patients contributed to achieving a median 4.9-month PFS. Previous evidence showed that apatinib exerted its anti-cancer effect not only via cytotoxicity but also via inhibition of migration and invasion by suppressing the RET/Src signaling pathway.19 However, further research on the precise mechanism of action in lung cancer is still required.

Several findings of our study are different from those of previous ones. First, all our patients were with lung SqCC, rather than non–small-cell lung cancer. Thus, our results would be more convincing for the usage of apatinib in advanced lung SqCC treatment. Second, we used apatinib at an initial dose of 250 mg/d, lower than the amount of apatinib applied in previous clinical trials. Zeng et al reported the efficacy of apatinib (250–425 mg/d) in SCC patients with a median PFS of 3.1 months,20 which was significantly less than PFS of our patients. As seen from the results, our patients achieved a median 4.9-month PFS and suffered less adverse effects. Interestingly, in the study of Hu et al,14 where the recommended dose was 500 mg daily, the rate of grade 3/4 toxicity was significantly decreased, but the efficacy was similar to that of the daily regimen of 850 mg in breast carcinoma. Therefore, we suggested that the dosage of apatinib had little effect on its efficacy but was related to the severity of side effects. Further investigation remains to be done to confirm the most suitable dosage of apatinib in patients with lung SqCC. Third, our study reported the median OS simultaneously, which might be a more valuable endpoint than PFS.

The toxicity profile was basically similar to that reported in earlier clinical trials,12–14 including hypertension, proteinuria, hand-foot skin reaction, hematological toxicities, fatigue, etc., most of which were grade 1 and 2. A phase III clinical trial showed that anti-angiogenesis side effects, such as hypertension, proteinuria and hand-foot syndrome, often indicated better clinical efficacy among patients with gastric cancer administered with apatinib.13 A retrospective cohort study of 269 patients with gastric cancer receiving apatinib in two phase III clinical trials further demonstrated that patients with side effects including hypertension, proteinuria, and hand-foot syndrome had a longer overall survival, progression-free survival, and disease remission rate.21 Therefore, these adverse reactions can be used as a basis for the establishment of a prognostic scoring system to predict the efficacy of apatinib. In our study, all six patients achieved PR had one of the three side effects, and none of the patients achieved PD had the above side effects.

However, there are several limitations to our study. First, 38 patients were included in our study, and the efficacy of the treatment could be evaluated in only 36 patients. The results of a larger-scale multicenter study would be more convincing. Second, the patients were treated with apatinib as first to fifth-line therapy based on their different status and willingness. Moreover, herein, we conducted a single-arm, phase II prospective cohort study, not a randomized controlled trail, which would have produced more persuasive results. A randomized placebo-controlled clinical trial needs to be conducted to further validate the efficiency and safety of apatinib in the treatment of lung SqCC patients.

Conclusions

In conclusion, our study indicated that apatinib might be a therapeutic option in advanced lung squamous-cell carcinoma patients and confirmed that anti-angiogenic therapy is feasible in lung squamous-cell carcinoma. However, further elucidation is needed for the determination of the optimal dosage, patients, and number of treatment lines.